Skip to content
Open access

Predictive value of 18F-FDG PET/CT PyRadiomics features using a tabular deep learning model for cancer-related cognitive impairment in patients with DLBCL without CNS involvement

Aug 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 46 references
Medicine

TL;DR

Tabular deep learning models based on handcrafted PET/CT PyRadiomics features showed preliminary potential for predicting CRCI in patients with non-CNS DLBCL, and a left occipital CT texture feature emerged as the highest-ranked model contributor in SHAP analysis.

Abstract

Objective To evaluate the predictive value of tabular deep learning models trained on handcrafted 18F-FDG PET/CT PyRadiomics features and clinical data for cancer-related cognitive impairment (CRCI) among patients with diffuse large B-cell lymphoma without central nervous system involvement (non-CNS DLBCL). Material and methods We retrospectively analyzed 112 non-CNS DLBCL patients who underwent brain 18F-fluorodeoxyglucose (18F-FDG)PET/CT. Based on Montreal Cognitive Assessment (MoCA) and Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scores, patients were classified into the CRCI group (n = 73) and the non-CRCI group (n = 39) and randomly partitioned into training (n=89) and test (n=23) sets at an 8:2 ratio. Five-fold cross-validation was performed within the training set for model development, and bootstrap resampling was used to estimate 95% confidence intervals for AUC. Radiomic features were extracted with PyRadiomics from automatically segmented brain regions using MOOSE120 software. These handcrafted PET/CT radiomic features and clinical variables were organized as structured tabular datasets; raw PET/CT images were not used as direct model inputs. Feature selection was performed using correlation coefficients. The performance of seven tabular deep learning models was evaluated using receiver operating characteristic (ROC) curves and decision curve analysis (DCA), and different input modalities (clinical, PET, CT, and combined) were compared. Shapley additive explanations (SHAP) were applied to interpret feature contributions. Results The AutoInt and Neural Oblivious Decision Ensembles (NODE) models showed the best predictive performance, achieving training areas under the curve (AUCs) of 0.905 and 0.904, and test AUCs of 0.858 and 0.808, respectively. DCA suggested potential clinical utility. In the modality-specific analysis, the AutoInt model integrating CT, PET, and clinical features achieved a training AUC of 0.905 and a test AUC of 0.858, representing the most favorable test-set performance among the evaluated AutoInt input modalities. A CT texture feature from the left occipital lobe emerged as the highest-ranked model contributor in SHAP analysis, with a mean absolute attribution score of approximately 0.0078. Conclusions Tabular deep learning models based on handcrafted PET/CT PyRadiomics features showed preliminary potential for predicting CRCI in patients with non-CNS DLBCL. Among the evaluated models, AutoInt achieved the most favorable performance in the exploratory internal test set. Multimodal integration of PET, CT, and clinical tabular features may provide complementary information for CRCI prediction. SHAP analysis identified a left occipital CT texture feature as the top-ranked model contributor; however, this finding should be regarded as exploratory rather than a validated biomarker.

Read PDF

Similar papers

Open access Aug 2026

Deep learning-radiomics-SUVmax integration from 18F-FDG PET/CT predicts synchronous distant metastasis in nasopharyngeal carcinoma

Objectives This study aimed to develop and evaluate deep learning (DL) models of primary tumor (T) and cervical metastatic lymph nodes (CMLNs) using fluorine-18 fluorodeoxyglucose positron emission computed tomography (18F-FDG positron emission tomography/computed tomography (PET/CT)) imaging for predicting synchronous...

Yun Zhang, Ying Cao, Shan-Shan Xu et al. · 0 citations
Open access Sep 2026

Clinical–Radiomics Nomogram Based on 18F-FDG PET/CT for Distinguishing Lymphoma from Cancer of Unknown Primary in Head and Neck Metastatic Poorly Differentiated Cancer

The clinical–radiomics nomogram shows promising potential for differentiating lymphoma from CUP in poorly differentiated cervical lymph node malignancies and warrants further validation in larger, multi-center cohorts before clinical implementation.

Wen Chen, Ming-Zhen Xu, Bing-Xin Gu et al. · 0 citations
Aug 2026

A Dual-Center, Interpretable Deep Learning-Radiomics Fusion Model for Distinguishing Nasopharyngeal Carcinoma from Nasopharyngeal Lymphoma Using FDG PET/CT.

RATIONALE AND OBJECTIVES Accurate differentiation between Nasopharyngeal Carcinoma (NPC) and Nasopharyngeal Lymphoma (NPL) is critical for clinical management. We aimed to develop an interpretable deep learning-radiomics fusion model using positron emission tomography/computed tomography (PET/CT) and validate it extern...

Meina Liang, Cheng-Mao Guo, Xiao-Yu Gao et al. · 0 citations
Sep 2026

18F-FDG PET/CT radiomics for prediction of BRCA mutations in high-grade serous ovarian cancer.

OBJECTIVE This study aimed to develop and validate a 18F-fluorodeoxyglucose PET/computed tomography (CT)-based radiomics model for predicting BRCA mutation status in patients with advanced high-grade serous ovarian cancer (HGSOC). METHODS A retrospective study of 124 patients with HGSOC who underwent preoperative PET...

Fang-Mei Jiang, Shu-Yong Liu, Chun-Li Liu et al. · 0 citations
Open access Aug 2026

18F-FDG PET/CT metabolic network connectivity in clinical staging of diffuse large B-cell lymphoma

Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common and highly heterogeneous subtype of non-Hodgkin lymphoma, and accurate staging is essential for treatment planning and prognosis. This study explored the value of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-F...

Jin-Hai Zou, H. Zou, Chang Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.